Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PVLA
stocks logo

PVLA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast PVLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PVLA is 132.55 USD with a low forecast of 70.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast PVLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PVLA is 132.55 USD with a low forecast of 70.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.800
sliders
Low
70.00
Averages
132.55
High
200.00
Current: 93.800
sliders
Low
70.00
Averages
132.55
High
200.00
Stifel
Buy
maintain
$87 -> $145
2025-11-24
Reason
Stifel
Price Target
$87 -> $145
2025-11-24
maintain
Buy
Reason
Stifel raised the firm's price target on Palvella Therapeutics to $145 from $87 and keeps a Buy rating on the shares. Despite the "tremendous outperformance of shares," the firm still sees room for upside, not just from the Phase 2 TOIVA proof-of-concept trial data for QTORIN rapamycin 3.9% in cVMs due in mid-December but also the "numerous value-creating programs" it sees coming from the QTORIN platform, the analyst tells investors.
Raymond James
Raymond James
Outperform -> Strong Buy
upgrade
$92 -> $143
2025-11-19
Reason
Raymond James
Raymond James
Price Target
$92 -> $143
2025-11-19
upgrade
Outperform -> Strong Buy
Reason
Raymond James upgraded Palvella Therapeutics to Strong Buy from Outperform with a price target of $143, up from $92. After further review of precedent studies and the broader rationale for QTORIN rapamycin in cutaneous venous malformations ahead of the mid-December Phase 2 TOIVA readout, the case for efficacy appears strong based on oral rapamycin data, prior QTORIN success in microcystic lymphatic malformations, and its favorable safety and absorption profile, the analyst tells investors in a research note. Although buyside expectations sit somewhat above Palvella's internal 30% improvement threshold, the upcoming readout is more likely than not to meet both benchmarks and reinforce the program's broad potential, Raymond James argues.
Canaccord
Buy
maintain
$90 -> $148
2025-11-13
Reason
Canaccord
Price Target
$90 -> $148
2025-11-13
maintain
Buy
Reason
Canaccord raised the firm's price target on Palvella Therapeutics to $148 from $90 and keeps a Buy rating on the shares. The firm said 3Q25 earnings was uneventful as everything is on track: top-line Ph2 CVM data is expected in mid-December and top-line Ph3 MLM data in 1Q26. Canaccord said the bigger news was announcement of a new product candidate; QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis (DSAP).
Oppenheimer
NULL -> Outperform
maintain
$100 -> $120
2025-11-11
Reason
Oppenheimer
Price Target
$100 -> $120
2025-11-11
maintain
NULL -> Outperform
Reason
Oppenheimer raised the firm's price target on Palvella Therapeutics to $120 from $100 and keeps an Outperform rating on the shares.
Chardan
Geulah Livshits
Buy
maintain
$73 -> $110
2025-11-07
Reason
Chardan
Geulah Livshits
Price Target
$73 -> $110
2025-11-07
maintain
Buy
Reason
Chardan analyst Geulah Livshits raised the firm's price target on Palvella Therapeutics to $110 from $73 and keeps a Buy rating on the shares after the company announced Qtorin pitavastatin for disseminated superficial actinic porokeratosis as its second product candidate. With a 50K U.S. cases, no FDA approved therapies, and mechanistic validation from academic studies using other topical statins, the program has a strong chance of technical success and a presents a "robust" commercial opportunity, the analyst tells investors in a research note.
H.C. Wainwright
Andres Maldonado
Buy
maintain
$95 -> $190
2025-11-06
Reason
H.C. Wainwright
Andres Maldonado
Price Target
$95 -> $190
2025-11-06
maintain
Buy
Reason
H.C. Wainwright analyst Andres Maldonado raised the firm's price target on Palvella Therapeutics to $190 from $95 and keeps a Buy rating on the shares after the company said it is adding QTORIN Pitavastatin as the new product candidate under the QTORIN platform for disseminated superficial actinic porokeratosis. The firm believes that expanding the QTORIN platform beyond Rapamycin to include a statin provides evidence of the breadth and scalability of the platform, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Palvella Therapeutics Inc (PVLA.O) is -23.50, compared to its 5-year average forward P/E of -11.85. For a more detailed relative valuation and DCF analysis to assess Palvella Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.85
Current PE
-23.50
Overvalued PE
-5.86
Undervalued PE
-17.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.55
Undervalued EV/EBITDA
-15.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6650.64
Current PS
0.00
Overvalued PS
19660.20
Undervalued PS
-6358.92
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

PVLA News & Events

Events Timeline

(ET)
2025-11-11
07:33:29
Palvella Therapeutics Announces Q3 EPS of $1.03, Exceeding Consensus Estimate of 84 Cents
select
2025-10-13 (ET)
2025-10-13
07:33:15
Palvella Secures Second Year of Funding from FDA's Office of OPD Grant
select
2025-09-24 (ET)
2025-09-24
06:04:54
Palvella Therapeutics broadens its QTORIN rapamycin development initiative
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-25Benzinga
Stifel Reaffirms Buy Rating for Palvella Therapeutics and Increases Price Target to $145

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
4.0
11-19Benzinga
Raymond James Boosts Palvella Therapeutics Rating to Strong Buy and Increases Price Target to $143

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

[object Object]
Preview
4.0
11-14Benzinga
Canaccord Genuity Reaffirms Buy Rating for Palvella Therapeutics and Increases Price Target to $148

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Palvella Therapeutics Inc (PVLA) stock price today?

The current price of PVLA is 93.8 USD — it has increased 2.06 % in the last trading day.

arrow icon

What is Palvella Therapeutics Inc (PVLA)'s business?

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

arrow icon

What is the price predicton of PVLA Stock?

Wall Street analysts forecast PVLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PVLA is 132.55 USD with a low forecast of 70.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Palvella Therapeutics Inc (PVLA)'s revenue for the last quarter?

Palvella Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Palvella Therapeutics Inc (PVLA)'s earnings per share (EPS) for the last quarter?

Palvella Therapeutics Inc. EPS for the last quarter amounts to -1.03 USD, decreased -73.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Palvella Therapeutics Inc (PVLA)'s fundamentals?

The market is revising Upward the revenue expectations for Palvella Therapeutics, Inc. (PVLA) for FY2026, with the revenue forecasts being adjusted by 9.09% over the past three months. During the same period, the stock price has changed by 68.46%.
arrow icon

How many employees does Palvella Therapeutics Inc (PVLA). have?

Palvella Therapeutics Inc (PVLA) has 14 emplpoyees as of December 05 2025.

arrow icon

What is Palvella Therapeutics Inc (PVLA) market cap?

Today PVLA has the market capitalization of 1.11B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free